Navigation Links
NHL in Medical News

NFL, NHL and NHLPA Team Up in Sports Concussion Education Campaign

DENVER, Oct. 17 /PRNewswire-USNewswire/ -- The National Football League (NFL), National Hockey League (NHL) and the National Hockey League Player's Association (NHLPA) have agreed to sponsor an educational program on sports concussions developed by the National Academy of Neuropsychology (NAN)...

Sports Icons Troy Aikman, Clyde Drexler, Mike Piazza, Ivan Lendl and Dara Torres are Among the Elite Named 2009 'Great Sports Legends'

... career total, seventh best in NASCAR modern era); recently, ESPN and ABC Sports broadcaster. Brett Hull - Known as "The Golden Brett"; a 2009 nhl Hall of Fame inductee; played 5 teams including the Calgary Flames, St. Louis Blues and Dallas Stars; current executive vice president of the Dallas S...

Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr

...lbis , Morgan Pressel , Brittany Lincicome and Erica Blasberg , as well other sports stars and celebrities including Vincent Lecavalier from the nhl and Doug Flutie from the NFL. "I'm thrilled with the strides Birdies for Breast Cancer has made thus far," said Cristie Kerr. "We look forwar...

Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe

...stration ("FDA") for pixantrone to treat relapsed or refractory, aggressive nhl in June 2009 and requested priority review, which if granted could lead to ...g cardiac disorders) for the treatment of relapsed or refractory aggressive nhl as determined by the FDA, the potential that the EMEA does not grant the MA...

Over 74,000 Participate in President Obama Teleforum on Healthcare Reform

...eforums, online polling and real-time measurement. Colorado-based Broadnet has worked with members of the United States Congress and teams in the NFL, nhl and NBA. Visit www.broadnetconnects.com for more information. ...

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

...form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of nhl accounting for 6 percent of all new diagnoses of nhl or approximately 3,000 new cases per year in the United States. Mantle cel...

Gene linked to increasingly common type of blood cancer

...odes. In NHL, tumors develop in lymphocytes, a type of white blood cell. Follicular lymphoma arises from B-cells, a specific type of white blood cell. nhl is the fifth most common type of cancer in the U.S., and is newly diagnosed in about 66,000 Americans each year, and annually kills nearly 20,000, acc...

ACL Repair Creator William G. Clancy, Jr., MD Inducted into AOSSM Hall of Fame

...uciate ligament reconstruction procedures, which are used by virtually all knee surgeons throughout the world today. The vast majority of NFL, NBA and nhl players requiring surgery for their ACL tears have had the "Clancy Procedure." His most recent work has clearly documented the bony landmark...

Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review

...nt trial of pixantrone for patients with relapsed or refractory, aggressive nhl who received two or more prior therapies and who were sensitive to treatmen...g cardiac disorders) for the treatment of relapsed or refractory aggressive nhl as determined by the FDA, the potential that priority review will not be gr...

Minor league hockey players unable to identify concussion symptoms, study says

...ce hockey while university and elite amateur players sustain rates of 4.2 and 6.6 concussions per 1,000 player hours. Concussions have forced many nhl players like Brett Lindros and Pat LaFontaine to retire early and others like Eric Lindros and goalie Mike Richter to stay off the ice for an extended...
NHL in Medical Technology

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that ...

Recruitment Completed in Ofatumumab NHL Pivotal Study

Summary: Genmab has Completed Recruitment of Patients in the Phase III Study of Ofatumumab in Rituximab Refractory Follicular NHL COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III st...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

Overview of 11 peer review publications presented in 'Future Oncology' SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies wit...

Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL

Potential NDA Submission in 2009 SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) announced today that enrollment is complete in the phase III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with relapsed di...

Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients

Proposed Phase III Trial Has the Potential to Demonstrate an Effect on a Serious or Life Threatening Aspect of This Disease SEATTLE, May 07, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today it received fast track designation from the U.S. Food and Drug Administration (F...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

...) compared to rituximab alone in relapsed indolent nhl Phase II; AZA I06- Pixantrone plus fluda... (70%) and ORR (89%) in multiple relapsed indolent nhl Cell Therapeutics, Inc. ("CT...ntrone clinical studies in aggressive and indolent nhl including follow-up data and subgroup analyses of ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...nt's T cells to seek out and destroy cancer cells. The poster presentation gave an update of an ongoing phase 1 trial of blinatumomab in relapsed nhl patients including a follow-up on response duration as well as pharmacodynamic activity(1). A dose-dependent clinical activity has been observed in th...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...may be cured with appropriate therapy(3). However, nhl patients have a high risk of relapse after initial...y. Results show that 33% of patients with relapsed nhl and Hodgkin's disease treated with everolimus expe...ts with relapsed/refractory aggressive or indolent nhl or Hodgkin's disease whose disease progressed desp...

Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting

...rone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive nhl as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority ...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

... either Hodgkin's or non-Hodgkin's lymphoma (NHL). nhl is the most prevalent type of lymphoma: the Nation... than 66,000 new cases and over 19,000 deaths from nhl in the United States in 2008. There are many diffe...he most common, or T-cell NHL. Though treatment of nhl has improved significantly, nearly 25% of patients...
NHL in Medical Definition

Hematopathology

...marily C81-C96 , D50-D77 ) White blood cells Lymphoid : Lymphoid leukaemia ( ALL , CLL , HCL ) • Lymphoma ( Hodgkin's disease , nhl ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thro...

Pathology

...marily C81-C96 , D50-D77 ) White blood cells Lymphoid : Lymphoid leukaemia ( ALL , CLL , HCL ) • Lymphoma ( Hodgkin's disease , nhl ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thro...
NHL in Biological News

Canadian Society of Exercise Physiology Annual Scientific Conference

...ns. PUBLIC FORUM: On Saturday, November 17 from 3:30 to 6 p.m. in Salon C, D and E, the Science of Ice Hockey Symposium will feature E.J. McGuire, nhl Director of Central Scouting. McGuire will share his thoughts on What it takes to get to the NHL. A series of studies will also be presented during t...

BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

...-cells." Biovest is now enrolling patients in a pivotal Phase 3 trial to test BiovaxID against follicular non-Hodgkin's lymphoma (NHL). Follicular nhl is an indolent (slow-growing) form of lymphoma not considered curable with existing therapies. The impressive findings from the Phase 2 clinical trial...
NHL in Biological Technology

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries -- DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL ...

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the Number of Patients to Approximately 81 COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

...Clinical Benefit in Relapsed/Refractory Aggressive nhl ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ ...r patients with relapsed or refractory, aggressive nhl who received two or more prior therapies and who w...apsed/refractory group of patients with aggressive nhl and look forward to completing the New Drug Applic...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... Activity of Blinatumomab in nhl and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presen...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

...III single-agent trial of pixantrone for patients with relapsed, aggressive nhl who received two or more prior therapies and who were sensitive to treatmen...pixantrone to prove safe and effective for treatment of relapsed aggressive nhl as determined by the FDA, the possibility that pixantrone could cause cumul...

Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting

...uximab, bendamustine, or rapamycin and additive with doxorubicin in killing nhl cells in vitro. In vivo results show that treatment with the combination of...mbined with rituximab, rapamycin, or bendamustine increases cell killing of nhl cells. Furthermore, the combination of TRU-016 and bendamustine displayed g...

CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture

...nal capital to continue to fund its operations, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive nhl as determined by the FDA, other determinations by regulatory, patent and administrative governmental authorities, competitive factors, technologica...

Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference

...and pricing assumptions. Summarized positive results from the phase III EXTEND trial of pixantrone in aggressive relapsed nhl for which it met the trial's primary endpoint, with patients treated with pixantrone achieving a high rate of confirmed and unconfirmed complete remis...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

...ember 5 to 8, 2009: Update on a phase 2 clinical trial with blinatumomab in ALL patients and final results from a phase 1 clinical trial in late stage nhl patients at the annual meeting of the American Society for Hematology (ASH) in New Orleans, LA. Additional expected Milestones in 2009...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

...to bring the first line consolidation for indolent nhl data to the FDA for potential label expansion in t...ractory, rituximab-naive, low-grade and follicular nhl based on studies using a surrogate endpoint of ove...system of vessels that drains fluid from the body. nhl can be broadly classified into two main forms - ag...
Other Tags
(Date:7/25/2014)... genes are switched on or off plays a key ... metabolism, UT Southwestern Medical Center researchers have found., The ... obesity and diabetes, since the transcription factor involved ... influence the body,s sensitivity to insulin and leptin signaling. ... regulation of food intake and sugar disposal, and obesity ...
(Date:7/25/2014)... Innerspire, LLC ( http://www.innerspire.com ) announced ... a Creative Enrollment Specialist. In this role, Greg will ... well as his accomplished design skills to further develop ... to service the creative marketing needs of ... with small business owners and individuals looking to accelerate ...
(Date:7/25/2014)... 2014 The American Brain Tumor Association ... “ABTA CommYOUnity™” during its annual patient and family conference ... the brain tumor community as we – the first ... support services and funding brain tumor research – extend ... brain tumor awareness and getting our materials and services ...
(Date:7/25/2014)... 25, 2014 There are 700,000 people in ... each day. Though when someone hears the words, “you have ... unsure of the next step and where to turn. , ... out that next step by providing and pursuing the answers ... Brian Olson, member of the ABTA’s Board of Directors and ...
(Date:7/25/2014)... July 25, 2014 Progress in understanding ... a new era of promising brain tumor treatments, according ... School, director of the Center for Neuro-Oncology, Dana-Farber Cancer ... annual Patient and Family Conference in Chicago, July 25-26, ... and new technology are impacting the development of new ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
Other Contents